Pharmaron Beijing
Pharmaron Beijing Co Ltd is a Chinese multinational contract research, development, and manufacturing organization (CRDMO) providing comprehensive pharmaceutical research and clinical development services to the global life sciences industry. The company delivers integrated laboratory services spanning drug discovery, synthetic chemistry, drug metabolism, pharmacokinetic analysis, preclinical toxicology, and clinical trial execution to major pharmaceutical and biotechnology enterprises worldwide. Its core business operations encompass pharmaceutical contract research, preclinical laboratory testing, chemical synthesis, and clinical development support. Revenue is derived primarily from fee-for-service research contracts, milestone agreements, and laboratory testing charges. Pharmaron Beijing holds a leading global market position in contract research and drug discovery services. The company is headquartered in Beijing, China, and its shares trade on the Shenzhen Stock Exchange and the Stock Exchange of Hong Kong.
10 of the funds FundTelligence covers report a position in Pharmaron Beijing.
- Legal name
- Pharmaron Beijing Co Ltd
- Sector
- Health Care
- Country
- China
- Funds holding it
- 10
Funds holding Pharmaron Beijing
- Handelsbanken Global Index Criteria — Handelsbanken · 0.03 % (full portfolio disclosed, September 2026)
- Handelsbanken Emerging Markets Index — Handelsbanken · 0.03 % (full portfolio disclosed, September 2026)
- BlackRock iShares MSCI EM IMI Screened UCITS ETF — BlackRock · 0.01 % (full portfolio disclosed, October 2026)
- KLP AksjeFremvoksende Markeder Indeks — KLP · 0.0 % (full portfolio disclosed, June 2026)
- Storebrand Emerging Markets — Storebrand · 0.0 % (full portfolio disclosed, October 2026)
- Storebrand Indeks Alle Markeder — Storebrand · 0.0 % (full portfolio disclosed, October 2026)
- Mercer Passive Emerging Markets Equity Fund — Mercer · 0.0 % (full portfolio disclosed, December 2025)
- Storebrand Indeks Nye Markeder — Storebrand · 0.0 % (full portfolio disclosed, October 2026)
Showing the 8 largest of 10 funds holding it.